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Abstract
Background—Osteoporosis is a common complication of aging. Alternatives to pharmacologic
treatment are needed for older adults. Non-pharmacologic treatment with low magnitude, high
frequency mechanical stimulation has been shown to prevent bone loss in animal and human
studies.
Methods—The VIBES (Vibration to Improve Bone Density in Elderly Subjects) study is a
randomized, double-blind, sham-controlled trial of the efficacy of low magnitude, high frequency
mechanical stimulation in 200 men and women aged 60 years and older with bone mineral density
T-scores by dual-x-ray absorptiometry between –1 and –2.5 at entry. Participants are healthy,
cognitively intact residents of independent living communities in the Boston area who receive free
calcium and Vitamin D supplements. They are randomly assigned to active or sham treatment and
stand on their assigned platform once daily for 10 minutes. All platforms have adherence data
collection software downloadable to a laptop computer. Adverse events are closely monitored. 174
participants were randomized and will be followed for two years. Almost all active subjects have
attained one year of follow-up. Bone mineral density is measured by both dual x-ray
absorptiometry and quantitative computed tomography at baseline and annually. The main
analysis will compare mean changes from baseline in volumetric bone density by quantitative
computed tomography in active and sham groups. Adherence and treatment effect magnitude will
also be evaluated. Secondary analyses will compare changes in three biochemical markers of bone
turnover as well as longitudinal comparisons of muscle and balance endpoints.
Results—The VIBES trial has completed its first year of data collection and encountered
multiple challenges leading to valuable lessons learned about the areas of recruitment from
independent living communities, deployment of multi-user mechanical devices using radio
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frequency identification cards and electronic adherence monitoring, organization of transportation
for imaging at a central site, and the expansion of study aims to include additional musculoskeletal
outcomes.
Conclusions—These lessons will guide future investigations in studies of individuals of
advanced age.
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INTRODUCTION
To test the potential benefits of low-level mechanical intervention in a clinically relevant
population at risk for osteoporosis, we designed a two-year, double-blind, randomized,
sham-controlled clinical trial of low magnitude mechanical stimulation (LMMS) in 200
women and men 60 years and over with low bone mineral density (BMD). Entitled
Vibration to Improve Bone Density in Elderly Subjects” and referred to as VIBES, the
clinical trial is designed to evaluate the efficacy of LMMS in the treatment of low BMD, and
other indices of musculoskeletal health, including balance, muscle mass and muscle
strength.
Osteoporosis, a disease characterized by the progressive loss of bone, is one of the most
common complications of aging.(1) To date, prevention of bone loss has been approached
principally through pharmacologic interventions, which have been shown to significantly
reduce fracture risk, yet these drugs target the skeleton without affecting other risk factors
for fracture such as muscle, balance and falls. Also despite the proven efficacy of these
drugs, many patients are reluctant to commit to long-term therapy because of significant side
effects,(2) and compliance is very poor.(3) Particularly in elderly individuals, it is desirable
to treat bone loss without pharmacologic intervention whenever possible because older
persons frequently take multiple medications, and thus are at an increased risk for drug
interactions and polypharmacy effects.
In addition to bone loss, older patients also may suffer from a loss of muscle strength and
age-related changes in neuromuscular control, which also contribute to the risk for falls and
fractures. There has been considerable interest in the role of environmental stimuli, such as
exercise, in preserving bone mass and morphology as well as muscle strength.(4) The most
effective approach to fracture prevention in older patients may be one that targets BMD and
reduces the risk for falls(5) by improving balance, muscle mass, and neuromuscular control.
The VIBES trial was designed specifically to test a unique device that delivered low
magnitude mechanical stimulation capable of stimulating bone formation(6-7) and




The VIBES trial involves men and women over the age of 60 years (with no upper limit on
age) with moderately low BMD. One of its unique aspects is the recruitment of individuals
over the age of 80 years who typically are not included in trials of osteoporosis prevention.
Another unique aspect of recruitment is the use of independent living communities (ILCs).
ILCs make it possible to: 1) install LMMS devices in “common” areas that attract the
attention of residents who may want to participate; 2) share equipment (a key feature to
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optimize resources); and 3) promote adherence to an intervention through communal social
relations. ILCs may be a single building or a campus of buildings where large numbers of
older persons reside. As congregate communities, they typically offer private apartments,
shared meals, housekeeping, laundry, transportation, and access to medical care. ILCs are a
thriving housing option for older adults and are expected to house as many as 18% of adults
age 75 and older by 2020. They already have become popular study sites for health-related
research.(9-10); however, they have not been used to conduct randomized, controlled,
clinical trials. The experience gained from the VIBES trial should be valuable to other
investigators planning clinical trials in these popular residential settings.
Inclusion and exclusion criteria ensure that trial participants do not have advanced
osteoporosis and are healthy enough to complete a two-year follow-up. Eligible trial
participants are not taking pharmacologic treatment for osteoporosis, and have osteopenic
BMD with T-scores between 1 and 2.5 standard deviations below young normal values in
either the total hip, femoral neck, trochanter, or lumbar spine. To maximize adherence with
the assigned intervention, candidates with cognitive dysfunction (scores greater than 12 on
the Short Blessed Test) are not enrolled.(11) ILC residents with BMD T-scores worse than
-2.5 or with fragility fracture within the past 5 years were excluded unless they had no
pharmacologic treatment options. Table 1 presents a complete list of inclusion and exclusion
criteria.
Participants were recruited only within ILCs. ILC enrollment required a formal discussion of
the study between community leadership and VIBES investigators. Prior to contact with
community residents, an advertising campaign using flyers, public announcements, and
community TV presentations was conducted. Following the campaign, the investigators and
the VIBES staff presented a community-specific information session with the residents.
Residents were presented with a study overview, given a chance to ask questions, and
encouraged to participate. For residents unable to attend the information session, a second,
informal session with refreshments was held later.
Screening was a multistage process, beginning with simple questions such as maintaining
residence in the community for the full calendar year, over the next two years, interest in the
study, willingness to stand on a vibrating platform for 10 minutes per day, and use of
osteoporosis drugs. Pre-screening was followed by the administration of informed consent
and a detailed review of remaining eligibility criteria. Residents who were judged eligible
after further questioning and cognitive function screening were scheduled for a dual-energy
X-ray absorptiometry (DXA) scan at the centrally located hospital, which performed these
measures for all ILCs. Transportation was provided and VIBES staff members accompanied
groups of residents. Following the DXA scan, eligible trial participants had phlebotomy for
screening labs, including a 25 hydroxy-vitamin D concentration, renal and liver function,
and thyroid stimulating hormone concentration. Residents with vitamin D values less than
15 ng/ml were offered vitamin D supplements and re-screened at a later date. Regardless of
eligibility, residents with abnormal findings at screening are immediately brought to the
attention of their regular physician. Residents who were eligible on all criteria in Table 1
were randomized and then underwent a baseline quantitative computed tomography (QCT)
scan of the hip and spine. All randomized participants were provided with free calcium
(1,000 mg) and vitamin D (800 IU) tablets for the duration of the trial.
Clinical Measures
Clinical measures collected at baseline, 12 and 24 months are listed in Table 2. The primary
outcome variables are quantitative computed tomography (QCT) measures of volumetric
trabecular bone density of the spine and hip. DXA measures are used only for screening and
safety follow-up. Secondary endpoints include biochemical markers of bone turnover and
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musculoskeletal health measures including standing balance, leg extension strength and self-
reported falls.
Volumetric Bone Density and Geometry by Quantitative Computed
Tomography—Quantitative computed tomography (QCT) is being used to evaluate
volumetric bone density (vBMD) and geometric indices at the lumbar spine and proximal
femur. Volumetric (or 3D) QCT imaging offers advantages over traditional DXA BMD
measurements because: 1) it can assess trabecular and cortical bone compartments
separately; 2) it can assess bone geometry, and 3) measurements are not confounded by bone
size.(12) Previous studies have shown that the responses to therapeutic intervention are
greater when assessed by QCT-based vertebral trabecular bone measurements than by DXA-
based spine BMD,(13-14) and thus QCT may be able to detect changes in trabecular bone
that would not be apparent by DXA-based BMD measures. QCT is particularly useful for
this trial since LMMS may preferentially impact trabecular bone,(15) and QCT measures not
only bone density, but also bone morphology.
Trial participants have QCT scanning of the proximal femur and lumbar spine (L1, L2) at
baseline, 12, and 24 months using a helical CT scanner operating at 120 kVp, 150 mAs, 48
mm field of view and 1 mm slice thickness. They are scanned simultaneously with a bone
mineral reference phantom (Image Analysis, Columbia, KY) that allows conversion of
Hounsfield units to BMD in mg/cm3 hydroxyapatite. All QCT image data are evaluated
using semi-automated methodology.(13, 16-18) Outcomes include integral, trabecular and
cortical volume, BMC and vBMD at these regions. The coefficient of variation (CV) for the
“total hip” trabecular volumetric BMD is 2.93%.(19) . For the spine (L1, L2), outcomes
include integral, trabecular and cortical tissue volume (cm3), bone mineral content (BMC, g)
and vBMD (g/cm3), as well as cross-sectional area. (See Figure 1). The CV for mid-
vertebral trabecular BMD is 2.93%.(19) For follow-up measurements, we are planning to
use a version of the QCT analysis software in which the densitometric and structural
analysis is integrated with a three-dimensional image registration program leading to
improved precision.(19) The radiation exposure for QCT scans is higher than for DXA
measurements; however, the exposure received from all of the radiographic procedures is
equivalent to a uniform whole body exposure of 3.7 rem, or 74% of the annual limit allowed
for a radiation worker such as an X-ray technologist. The exposure received in VIBES is
comparable to other every day risks.
Dual-Energy X-ray Absorptiometry (DXA)—DXA is used to screen the BMD of trial
candidates as well as to monitor for significant bone loss one year after enrollment. At
screening, residents undergo hip and spine scans to determine whether the BMD T-score is
osteopenic (lower than –1 but greater than –2.5). The DXA is repeated after one year and the
change in total hip BMD is calculated. Bone loss of greater than 8% at the total hip is a
safety-monitoring trigger for the referral of the participant to his/her personal physician.
In the first version of the VIBES study design, we considered a multicenter approach with
DXA-derived BMD as the primary outcome. The peer review of the design suggested that it
was premature to use a multicenter approach. Consequently, by designating CT-derived
bone density with its greater sensitivity to change over short time intervals as the primary
outcome instead of DXA we reduced the scope of the trial to a single recruitment center
with a smaller sample size. One of the advantages of having both DXA and QCT in the
same individuals is that changes observed during the study in one imaging modality can be
compared to the other. Previous osteoporosis clinical trials have relied exclusively on DXA
for measurement of skeletal responses to treatment.
Kiel et al. Page 4













Biochemical Markers of Bone Turnover—An important aim of this study is to use
serum assays of biochemical markers of bone formation and resorption to understand the
mechanism by which LMMS increases bone mass. LMMS is anabolic to bone and may
increase bone mass through an increase in bone formation. However, because there are few
data on the effects of LMMS on bone turnover, our hypothesis is based on the effects of a
well-established anabolic agent, parathyroid hormone (PTH), on bone turnover markers in
studies of PTH in human volunteers with osteoporosis. PTH is associated with early and
rapid increases in markers of bone formation, followed by increases in both bone resorption
and bone formation.(20) The early phase when PTH stimulates bone formation to a greater
extent than bone resorption, has been termed the “anabolic window.”(21)
To study the effects of LMMS on bone remodeling, we are storing serum at -70 C to
measure bone formation and resorption markers. Procollagen type 1 N-terminal peptide
(P1NP) is cleaved from newly formed collagen type 1 polypeptide and reflects the earliest
phase of bone formation. It is also the formation marker that rises earliest in response to the
anabolic effects of intermittent PTH injections.(21) The bone resorption marker, serum C-
terminal telopeptide of type I collagen (CTX), originates from the non-helical region of the
collagen molecule. Serum P1NP, BSAP and CTX are measured at baseline, and at 1, 3, 6,
12, and 24 months in both treatment groups. Specimens will be thawed once and processed
batch-wise in single assay runs. If LMMS functions as an anabolic agent, we expect to
observe increases in all three markers in the following order: P1NPfirst, followed by CTX.
An increase of 20%, 1/3 to 1/6 of that observed with PTH, will be clinically important and
the study is powered to detect treatment group differences of this magnitude.
Postural Stability—In the original VIBES design, postural stability was not included.
Subsequently, more information had emerged suggesting that LMMS may have salutary
effects on the neuromuscular system by providing the higher frequency of muscle stimuli
that typically declines due to age-related loss of type II muscle fibers. The type II muscle
fiber is involved in maintaining upright posture. Therefore we added relatively inexpensive
and non-invasive measures of postural stability at baseline, and at 1 and 2-year follow-up
examinations, as a means of assessing whether LMMS helps to slow the loss of postural
stability that typically parallels aging. Center of pressure measurements are performed on an
eight-channel force plate (Kistler, Winterthur, Switzerland) using an eight-channel
amplifier, an analogue-digital converter, and Bioware 3.2.6.104 software. Data are sampled
at 1000 Hz, low-pass filtered at 50 Hz, and stored for later analysis.
Participants are instructed to stand as still as possible with hands at sides, eyes open and
directed ahead, and feet placed at shoulder width. Four minutes of data are collected during
this quiet stance. The collection of postural stability data is automated and variables are
defined using a custom MATLAB program (version 7.0.1, The MathWorks, Natick,
Massachusetts). Operators are blinded to participant treatment group to minimize bias.
Muscle Strength by Isometric Hand-Held Dynamometry—Based on observations in
younger individuals that LMMS increases muscle area,(8) we use an inexpensive measure of
muscle strength with good reliability and minimal participant burden. An isometric hand-
held dynamometer (Lafayette Manual Muscle Test System Model 01163) is used to measure
right leg extension strength at baseline, 12 and 24 months. It is placed on the anterior surface
of the tibia 6 cm above the lateral malleolus. Participants practice one leg extension before
three measures of muscle strength are recorded.
Self-Reported Falls—Various approaches to ascertainment of falls were considered.
Based on previous experience from a longitudinal study of falls,(22) it was recognized that
monthly falls calendars would created undue workloads on the VIBES staff and trial
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participants. We collect self-reported falls every other month using a brief self-administered
questionnaire that is returned by mail. When fall report questionnaires are not returned,
VIBES staff members contact study participants to remind them. We initially were
concerned that trial participants would be reluctant to divulge their personal experience of
falling, for fear that their report could lead to placement in a more supervised residential
setting. Instead we found that we have almost perfect compliance with the fall forms, and
that many of the participants openly discuss their falls and their fears of falling and injury
resulting from them.
Randomization
Trial participants are enrolled into the study and randomized to active or sham intervention
after successfully completing all of the screening measures. Treatment group assignment
and platforms are color-coded so that study participants and VIBES staff remain blinded to
treatment assignment.
Randomization is stratified by ILC, gender and BMI to ensure balance between treatment
groups. Two BMI randomization strata are based upon the median BMI for NHANES III
participants 65 years and older with the same T-scores used in VIBES (BMI= 24.0).
Because of the potential for relatively few individuals in a community to pass screening, the
randomization schedule was designed with several small blocks at the beginning of each
stratum to avoid potential treatment imbalance because too few participants were assigned to
one or more of the four stratification groups.
CURRENT STATUS OF THE VIBES TRIAL
Enrollment
As of May 2009, 21 independent living communities had been enrolled, 304 participants had
been screened and 174 were randomized.
Treatment with Low Magnitude Mechanical Stimulation (LMMS)
All participants stand on their assigned platform for one 10-minute session each day. At
least two platforms are available in each ILC and they are used by study participants for
their sessions at any time throughout the day. It has been shown that daily 10-minute periods
of a high frequency, low magnitude mechanical signal were sufficient to stimulate bone
formation in humans,(8, 23) and that compliance remained high given this challenge, even
in an elderly population similar to the VIBES participants .(24)
Platforms require access to a standard electrical outlet. The top plate of each device is
suspended over the base by a set of compression springs. Force input to the platform is
provided by a single, low force (18N) electromagnetic linear actuator (BEI model LA18-18,
San Marcos, CA) capable of imposing acceleration of up to 1 g (9.8m/s2) on individuals
weighing up to 100 kg over 400 Hz. Accelerometer feedback from the plate surface adjusts
vertical displacement of the platform to compensate for participant motion or positional
changes.
Active LMMS and sham control platforms are engineered to look and sound the same, and
are programmed to activate sessions when the participant swipes his/her radio frequency
identification card (RFID) card (Figure 2). The engineering and presentation of sham
platforms is one of the unique achievements of the VIBES trial. Because the high frequency
(0.3 g) and low magnitude (30 Hz or cycles per second) of LMMS vibration is barely
perceptible to participants standing on the active device, it was not difficult to construct
sham platforms emitting similar audible humming sounds indistinguishable from active
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devices. In our pilot studies, participants could not discriminate between the active and sham
platforms when queried at the end of a six-month trial.(24) In addition to the configuration
of the platforms, color-coded RFID cards ensure that each participant uses the correct
platform. The RFID cards activate only the platform to which the subject is assigned.
Nevertheless, there is a chance that if individuals become unblinded, they could share this
with others at the site using the same assigned platform. To avoid this as much as possible,
the investigators and staff inform the trial participants that they should not try to figure out
which platform is active and which one is sham. In this age group, we have observed that
participants take these recommendations to heart and do not attempt to unblind others.
Adherence Assessment
Adherence information (participant ID, time on, time off, total session time) is recorded
electronically, stored by the platforms, and downloaded at regular intervals. This method of
collection of electronic adherence data was developed by VIBES and has not been used in
previous studies.
During the first week of study intervention in each ILC, research assistants were present
throughout the 10-minute sessions to familiarize participants with the safe operation of the
equipment and use of RFID cards, and to reinforce daily use of the platforms and sign-in
logs. To maximize adherence, participants are encouraged to choose the most convenient
time of day to complete their 10-minute session. They are told that the device automatically
records the date, start and end time of their sessions because of their unique RFID card.
They are instructed not to exchange RFID cards with other participants or to use platforms
not coded with their assigned color. Sign-in logs also are used to detect non-adherence.
Participants whose adherence has declined over time are contacted to discuss reasons for
non-adherence and options to improve adherence to the trial regimen. At each annual study
examination, adherence to the recommended daily intakes of calcium and vitamin D are
encouraged.
Adverse Event Monitoring and Notification
Vibration, particularly in the frequency domain of 5-15 Hz where resonance of the spine can
occur,(25) is considered a key etiologic factor in low back pain,(26) and a causal factor in
circulatory disorders such as Raynaud's Syndrome, blurred vision, and hearing loss.(27)
Research has focused on attenuating the transmission of whole body vibration to the
skeleton, with the widely held presumption that high frequency vibrations are pathogenic to
the musculoskeletal system,(28) and may even cause percussive injuries to the brain.(29) In
cases where vibration is unavoidable,(30) exposure limits have been recommended by the
National Institute of Occupational Safety and Health, (NIOSH), Centers for Disease Control
(CDC), and the International Organization for Standardization (ISO).(31) However, the level
of vibration used in VIBES is very low (e.g., generating less than 10 microstrain on the
cortical bone surface),(32) compared to the strain generated by walking ( > 1000
microstrain).(33) The vibration level is 50x less than vibration levels used in studies of
muscle building in athletes, where devices delivered 8-15g of vibration, far exceeding the 1
minute threshold limits mandated by ISO and NIOSH.(28, 34) Therefore, adverse events in
VIBES which can be attributed to the vibrating platform are not expected to be frequent or
severe; however, participants aged 60 years and older are expected to have many unrelated
comorbidities.
Balancing the low anticipated rate of adverse events due to LMMS with the relatively high
rate of expected events related to the age and comorbidities of participants, the VIBES study
uses a conservative definition of an adverse event as an undesirable medical occurrence
(sign, symptom, or diagnosis) or worsening of a pre-existing medical condition that occurs
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after the beginning of treatment. Early experience with reported adverse events highlighted
the potential for very large numbers of events in the VIBES age group. The workload
created by having to record the large number of common age-related events, such as
musculoskeletal pain, taught us that a more specific pre-study definition of reportable events
for a low risk device like the LMMS platform is preferable to a more standard broad
definition used in trials of devices and drugs that have a greater potential for unexpected or
unknown adverse events. The advanced imaging used in VIBES resulted in some
incidentally discovered abnormalities on CT scans (i.e., tumor masses and aortic aneurysms)
that necessitated the development of a systematic approach to the notification of health care
providers. Non-serious adverse events for each participant are tracked from the first report to
subsequent resolution with an event/report numbering system.
Serious adverse events (SAEs) are defined as significant hazards or side effects that may be
fatal or life threatening; require in-patient hospitalization or prolongation of an existing
hospitalization; be persistent or significant disabilities; or be other significant medical
hazards. Detailed information is collected on SAEs, including a description of symptoms,
possible causes, related medical conditions, relationship to study intervention, and narrative
comments and assessments.
For both serious adverse events and non-serious adverse events, their relationship to the
LMMS device is classified by the study physician as: definitely unrelated (virtually no
possibility), unlikely to be related (very little probability), possibly related (a small chance),
probably related (a reasonably high likelihood), or definitely related (a very strong
likelihood). For all events related to the LMMS device, medical records are obtained using a
signed release from the participant. All platform-related events are followed until they are
resolved. An independent Data and Safety Monitoring Committee meets every six months to
review adverse events and data quality.
Organization of the VIBES Trial
Central imaging—The organization of the VIBES trial to transport all participants to a
single central imaging facility was an important lesson learned. QCT imaging of volumetric
bone density is subject to considerable measurement error due to machine differences and
technologist differences, making the central imaging preferable to the use of multiple
imaging centers. The use of multiple imaging centers might be perceived as having less
participant burden in terms of travel time; however, we learned that even transportation
times of 45 minutes are acceptable to participants, especially when groups of participants
travel together. Group travel also helped to create rapport with VIBES staff and among
participants from a given ILC.
Quality assurance—All VIBES personnel attended a central training session prior to
collecting of data and were certified in standard data collection techniques. To minimize the
variability in the primary QCT outcomes, one primary technologist was designated to
perform scans, with three back up technologists also trained in the protocol of QCT scan
acquisition.
To ensure that all active LMMS platforms are delivering the appropriate mechanical signal,
and to be able to replace faulty equipment, all devices are calibrated at baseline, and at
monthly intervals throughout the study to monitor for the unlikely event of drift. Calibration
is performed by an unblinded “device monitor” who has no contact with study participants.
We originally did not anticipate the need for such a person in the VIBES trial; however we
now recognize the importance of such personnel when technical monitoring of devices is
required in a clinical trial.
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Quality control of QCT scan analyses is carried out in the QCT analysis program at the
central imaging hospital. As with analysis of DXA images, data are added to the program
database only after a quality assurance stage in which the operator confirms that the bone
regions determined by the analysis are acceptable, and the key BMD variables, calibration
phantom slopes and Hounsfield Unit values are found to be within pre-determined
constraints. To relate the BMD measurements from VIBES to other studies, the QCT
machines were calibrated prior to beginning the study to reference spine phantoms with
anatomically correct contours (European Spine Phantom, QRM, Erlangen Germany and
CIRS Torso Phantom, CIRS, Norfolk Virginia.). Weekly quality control measures are
obtained by scanning the hydroxyapatite density phantom (Image Analysis, Columbia KY).
Results from these quality control scans are processed and “red-flag” values are established
that initiate corrective action whenever deviation from accepted limits occurs.
The DXA technologist was trained in all scanning and analysis procedures using
manufacturer training standards. Quality control procedures include scanning a Hologic
spine phantom on each day that participants are scanned. Longitudinal DXA machine
performance is also monitored for drift using this phantom. The study physician reviews
results from the daily DXA quality control scan at monthly intervals to ensure that the
values are within accepted limits as specified by the manufacturer. All DXA analyses are
reviewed by one of the investigators, and are re-analyzed if problems are found. Finally, the
study physician reviews the longitudinal assessment of BMD for all participants without
being aware of treatment assignment.
Statistical Analysis
Analysis of Changes in vBMD—The main analysis for the primary study outcome will
compare the mean changes from baseline in vBMD measured by QCT in the active and
sham groups at the end of two years. If the variances are statistically equal, the two-group t-
test (equal variances)(35) will be used, and if they are not equal the two-group Satterthwaite
t-test(36) will be used instead. Intention-to-treat will be used for treatment effect assessment
of the primary outcome. Subjects unable to continue the assigned intervention are asked to
have the annual assessments. For participants who are unable to carry out the assessments,
the last observation will be carried forward.
Several secondary analyses of the primary outcome will be performed. An assessment of the
relation between treatment adherence and the magnitude of the vBMD treatment effect (i.e.,
the relationship between the number of sessions completed, and cumulative minutes spent
on the platform, and bone density treatment effect) will be performed using Generalized
Estimating Equations (GEE) models.(37) In addition, an adjustment of the primary study
outcome for potentially confounding factors will be made using a GEE model so that the
treatment effect is adjusted for other factors, such as age, gender, or physical activity.
Finally, an assessment of the change in vBMD within the active group will use random-
effects models(38) stratified by treatment group.
We want to emphasize the importance of assessing change within both groups. If a
significant difference in the vBMD change between active and sham groups is observed at
24 months, the active group may have improved significantly while the sham group was
unchanged or declined, or the sham group may have declined substantially but the active
group remained the same. These two very different scenarios have different implications for
the intervention. For this reason, we will evaluate the magnitude and significance of the
change from baseline to follow-up in the active group.
Longitudinal models, such as GEE(37) or random effects models(38) will be used to analyze
the serial vBMD measures of each participant across the 2- year follow-up period. GEE
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models will be used when we focus on differences in population-averaged outcomes (i.e.,
active versus sham group differences at follow-up). Random effects models will be used
when the emphasis is on change in a participant's outcome across time (i.e., trend over time).
(38-40)
An adaptation of the Lan-DeMets(41) procedure will be used for assessing the primary study
outcome for interim “looks” at the data. It is based on the work of Pampallona, Tsiatis and
Kim(42-43) and allows for flexible interim monitoring while simultaneously preserving both
the type-I and type-II errors of the study. Both alpha and beta spending functions will be
used; alpha for efficacy and beta for futility.(44) The rate at which the alpha and beta are
spent is a function of the total outcome available at the time of the interim analysis. A
stopping boundary that preserves the spirit of the O'Brien-Fleming stopping boundary(45)
will be used. The software package East(46) will be used for the monitoring of the primary
study outcome. No interim looks at the data have been requested by the DSMB to date.
Analysis of biochemical markers
Biochemical markers will be analyzed using approaches similar to those described above for
vBMD. The main analysis for bone formation and resorption markers will compare the
mean change from baseline in each biochemical marker in the active and sham groups using
a two-group t-test (using Satterthwaite adjustment if the variances are unequal).
Several secondary analyses will be performed, including an assessment of the relation
between treatment adherence and the magnitude of the biochemical marker treatment effect
(i.e., the relationship between the number of sessions completed, and cumulative minutes
spent on the platform, and biochemical marker of bone turnover). Similar to the primary
outcome, secondary analyses will also include an assessment of the change in each
biochemical marker within the active group and adjustment of the biochemical marker
outcomes for potentially confounding factors. Non-linear associations between vBMD and
factors such as cumulative minutes spent on the platform might suggest a dose-response
relationship, i.e., there may be “diminishing returns” in vBMD gains after a certain time
spent on the platform.
Sample Sizes
All sample size and power calculations were computed using the software package nQuery.
(47) To determine the sample size for the primary outcome of trabecular vBMD as
determined by QCT, we assumed a two-group t-test with equal group sizes and an 8%
difference in outcomes between the active group and the sham group at the end of two years.
This estimate was based on a conservative 3% per year increase in vBMD (6% over 2 years)
in the active group and a 1% per year decrease in vBMD (2% over 2 years) in the sham
group. The 3% per year increase expected in the active group was based on conservative
extrapolations from a clinical trial of parathyroid hormone in osteoporosis.(48) In the
placebo group, data from a drug study supported our estimated two-year loss of 2% in a
placebo group treated with calcium and vitamin D.(49) With 200 participants (100 active
and 100 sham), and an attrition rate of 18%, we expect 82 participants per study group (i.e.,
a total sample of 164 at the end of the study), giving us 91% power to detect an 8%
difference in outcome between the active group and the placebo group (2-sided α = 0.05).
With 82 participants in the treatment group, we expect 97% power (1-sided α = 0.05) to
detect a 6% increase of BMD from baseline in the active group to the end of 24 months. The
18% attrition rate was estimated based on our pilot study.(24)
Table 3 presents the projected differences for each of the secondary outcomes and the power
associated with that difference. The treatment group comparison assumes a two-group t-test
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with equal sample sizes and a two-sided alpha=0.05. The test of difference from baseline to
the 24 months of follow-up assumes a one-group t-test of the differences from baseline to 24
months with a one-sided alpha=0.05.
LESSONS LEARNED
Recruitment
The challenges encountered by VIBES investigators during recruitment have led to
methodologic and substantive innovations in the original design of the study. Perhaps the
most important problem faced was one of recruiting osteopenic seniors not taking
osteoporosis medications in an environment where prompt treatment of even moderately low
BMD is increasingly common. Investigators found it necessary to recruit more than three
times the number of ILCs initially expected instead of the planned six ILCs) with minimal
increase in the number of VIBES research staff. Some efficiencies of scale were built into
the original study design since participation in the intervention took place within the ILCs.
The VIBES team obtained informed consent and screened all residents within a short time
frame and within a few weeks was ready to screen at the next community. Initial recruitment
sessions were held in a group setting in each ILC. Small groups from each ILC traveled to
the imaging center for baseline DXA and CT scans, greatly reducing transportation costs. In
some cases, transportation has been supplied by the ILC using their own vehicles and
drivers. Screening phlebotomy was also performed on-site, which was convenient for
participants. Because many ILCs had medical services, ILC medical staff sometimes helped
with difficult phlebotomies. Finally, many fewer platforms were required because ILC
residents shared devices placed in common areas.
As recruitment progressed and enrollment numbers lagged behind expectations, a number of
strategies were developed to further increase screening yields. Given a choice of ILCs,
VIBES targeted larger communities in the Boston area in an effort to enroll the largest
number of participants. Pre-screening participant information, including medications, was
collected at introductory information sessions in order to eliminate residents taking
exclusionary medications as early in the screening process as possible. Investigators also
learned to make more effective use of ILC personnel and publicity distribution systems
during recruitment, including the production of short TV programs and “infomercials” for
airing on ILC broadcast systems. Body mass index eligibility criteria and a 2-week
adherence run-in period were dropped within several months of study initiation.
Investigators also re-screened residents of platform-equipped ILCs in search of eligible new
residents or residents who had not been screened initially. These changes greatly improved
the efficiency of VIBES recruitment so that a relatively small VIBES staff working at 21
ILCs was able to enroll and randomize 174 participants as of May 2009 with minimal
increase in resources. Sharing baseline BMD results with residents also served as an
incentive to participate.
Technical Development and Electronic Data Collection
Other lessons were learned about the use of the vibrating platforms and the electronic
recording and downloading of adherence data. To our knowledge, these methods have no
precedent in previous studies. Significant effort was contributed by the device manufacturer
in engineering platforms with data collection equipment that permits files to be downloaded
to a laptop computer. Platforms are either active or sham and are programmed to operate
only for trial participants using an RFID card linked to their treatment group. RFID cards are
assigned to each eligible subject at randomization by the Data Coordinating Center. Cards
contain ID information and were attached to lanyards to minimize loss. Platforms also were
equipped with electronic read-outs providing participants with cues on device status. When
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the electricity failed or the plug was removed from the electric wall outlet, the equipment
had to be reset manually. This problem was discovered early and participants were trained to
reset the equipment to ensure optimal functioning. Other problems occurred when software
errors in the electronic adherence programs of some platforms led to inaccurate recording of
session clock times. Regular monitoring of adherence data detected an unusual number of
duplicate sessions on the same day accompanied by an unusual number of missing sessions.
These errors were rectified and the lesson learned was that this type of data requires careful
monitoring.
Special technical problems were encountered during the engineering of the sham platforms
to make them difficult to distinguish from active vibrating platforms. They were designed to
emit auditory cues, identical to those emitted by active platforms. Platform read-outs on
session status were identical in both treatment groups.
Problems emerged related to the greater number of platforms required to equip the greater
number of ILCs enrolled. Investigators developed methods of re-cycling unused platforms in
ILCs with small numbers of randomized participants. Unused platforms are sent back to the
manufacturer for re-programming and re-numbering and are reused in another community.
Devices that malfunction are repaired and similarly re-cycled.
The groupings of platforms in ILC common areas allowed multiple users per machine
without threatening the blinding of participants. Because platforms are not easily moved,
they were placed in a central location affording access to all participants of the ILC;
however, placement nearby or in the same building was not always possible due to space
considerations, the need for an electrical outlet, and safety of others who might be near the
equipment. The administrative staff of one ILC designated a single area for participants
from two adjacent buildings rather than using each building as a site. As a result, potentially
eligible participants withdrew during the screening process. In another ILC, the distance
between the platforms and one of the subject's apartments was too far for him to walk. Thus
flexibility in the use of shared equipment may be the best approach when resources permit.
Outcome Measures – Sensitivity to Change
As previously mentioned, the VIBES trial was initially designed to be a multicenter clinical
trial with each center enrolling its own ILCs. However when peer reviewers recommended a
single recruitment center with a smaller sample, we changed our original primary outcome
measure from DXA-derived BMD to QCT BMD. This change in the primary outcome
afforded greater sensitivity to change such that our power was adequate with a smaller
sample size. Using the QCT outcome measure also allowed us to examine specific bone
compartment changes. These advantages came at the cost of the additional transportation to
the hospital for the CT scans, additional radiation exposure which resulted in a small number
of potential participants who declined to participate, the expense and special training of CT
technologists, and the adaptation of image analysis software for longitudinal analyses.
Addition of Musculoskeletal Health Outcomes
Finally, other lessons were learned during the start-up phase of the trial leading to the
addition of important muscle and balance secondary outcomes to the Protocol. The VIBES
design, as originally conceived, evaluated a potentially bone active intervention. Endpoints
focused on bone density, architecture, and turnover alone. However, investigators quickly
recognized that the intervention may affect muscle as well as bone and that use of the QCT
technology leads naturally to the measurement of muscle and balance related endpoints at
little extra cost. Consideration of the literature on musculoskeletal health and postural
stability related to falls in older people provided other reasons for the addition of muscle and
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postural stability endpoints to VIBES, provided that they could be measured at minimal cost
to the study and time burden to participants. Consequently, investigators expanded the study
design to include measurements of: 1) muscle mass by QCT in the area of the lower spine
from the same scans used to read spinal bone density and architecture; 2) muscle strength in
the right leg by a hand-held dynamometer done at the time of the QCT measurement; 3)
lower extremity function and balance using the Short Physical Performance Battery done at
the time of the QCT measurement; and 4) postural stability with a 4-minute trial of double-
legged stance on a donated force plate done at the time of the QCT measurement. This
expansion of scope also had a considerable impact on the level of interest expressed by
potential participants. We encountered multiple questions about balance and equilibrium
during our recruitment, and many individuals agreed to participate in the hope that they
might learn more about their musculoskeletal health and improve their balance. Their
interest underscored the appeal of more broadly defined musculoskeletal endpoints in
clinical trials of older persons.
CONCLUSIONS
VIBES is the largest study of LMMS in participants over the age of 60 years with state of
the art QCT outcome measures of bone health, muscle, and balance outcomes. Data analysis
will compare QCT with DXA primary outcome measures in the VIBES population. Our
results will contribute important information on the use of QCT primary endpoints and on
whether the use of LMMS for 10 minutes daily will reduce falls and fracture risk factors in
older persons. It includes participants of both genders over the age of 80, who are most
likely to fall and who are concerned about osteoporosis, balance, and polypharmacy effects.
The VIBES investigators have solved many of the practical problems associated with
measurements made on independent-living residents of retirement communities, and the use
of active and sham vibrating platforms. The trial also has eliminated the need for using
costly per-person intervention equipment by developing flexible methods for centralized
intervention and electronic adherence data collection.
We expect that future designers of bone health studies in older participants will follow the
same logical progression to a less bone-centered, broader picture of musculoskeletal health
and encounter many of the same problems as VIBES. Our experience should provide a
valuable guide to future efforts.
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Representative images from quantitative CT scans performed on the lumbar spine and
proximal femur. The planes shown for each region on the left are displayed in cross-section
on the right.
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The Low Magnitude Mechanical Stimulation plate with a surrounding frame for ensuring
stability while standing.
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Table 1
Inclusion and exclusion criteria used for the VIBES randomized sham-controlled trial of Low Magnitude
Mechanical Stimulation
Inclusion Criteria:
English speaking: Ability to speak and understand English
Age/Gender: Men and women ≥ 60 years
General health: Absence of terminal illness (no illness expected to result in death within the next 12 months
Bone Mineral Density: A BMD gender specific T-score in either the total hip, femoral neck, trochanter, or L1-L4 spine between −1 and −2.49
inclusive. Subjects with a T-score of −2.5 or less are included if they have no options for osteoporosis medications
Cognitive status: Capable of following protocol and providing informed consent; scoring <12 on the Short Blessed Test of cognitive function.
Exclusion Criteria:
Ponderosity: Subjects who weigh 250 pounds or more.
Physical activity: Immobilization within the last year, nonambulatory, or prolonged bed rest for greater than 3 months in the last year.
Malignancy or renal disease: Malignancy other than cured thyroid cancer or skin cancer. Estimated glomerular filtration rate below 30.
Orthopedic: Bilateral hip replacement ever and hip replacement or internal fixation, total knee replacement, both hip and spine (L1-L2) surgical
hardware, or lower limb amputation, or a history of a fragility fracture within the past 5 years except if the subject has no options for
osteoporosis medications
Medications: Glucocorticoids, suppressive doses of thyroid hormone as determined by screening TSH, phenytoin, phenobarbital,
carbamazepine, estrogen/testosterone replacement, SERMs, PTH, or bisphosphonates >1 month in the past year, calcitonin therapy within the
preceding month, fluoride therapy at any time, rosiglitazone, pioglitazone, inhaled corticosteroids greater than a prednisone equivalent dose of 5
mg per day.
Laboratory values: 25-hydroxyvitamin D levels less than 15 ng/mL, calcium level greater than the upper limit of the laboratory range.
Availability: Not available for ≥3 months per year because of travel to warmer climate or other seasonal residence
Other: Paget's disease, hyperparathyroidism, rheumatoid arthritis or other connective tissue disorders requiring systemic treatment with disease
modifying drugs, or a history of Cushing's syndrome by history.
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Table 3
Projected differences and power for statistical tests of secondary outcomes in the VIBES randomized, sham-
controlled trial of low magnitude mechanical stimulation
Outcomes Treatment Group Comparison Difference from Baseline to 2nd Year of follow-up in
Treatment Group
Difference Power Difference Power
Biochemical markers of Bone Turnover
    CTX 20% 84% 20% 90%
    BSAP 20% 90% 20% 95%
    P1NP 20% 95% 20% 98%
Musculoskeletal health
    Quadriceps isometric strength 15% 84% 10% 86%
    Falls 15% 88% 10% 90%
Balance
    Mean velocity 15% 91% 10% 92%
    Root mean square distance 15% 88% 10% 92%
    Mean frequency 10% 88% 7.5% 83%
    Centroid frequency 10% 86% 7.5% 82%
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